SciELO - Scientific Electronic Library Online

 
vol.59 número1Prevalencia de adenocarcinoma prostático incidental tras adenomectomía suprapúbica con o sin biopsia prostática previaSuprarrenalectomía laparoscópica retroperitoneal como opción minimamente invasiva en el tratamiento de tumores adrenales índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Archivos Españoles de Urología (Ed. impresa)

versão impressa ISSN 0004-0614

Resumo

MAROTO, José Pablo et al. Allogeneic transplantation or peripheral blood hematopoietic stem-cells with low intensity conditioning for the treatment of a metastatic clear cell carcinoma: Preliminary results after two years of follow-up. Arch. Esp. Urol. [online]. 2006, vol.59, n.1, pp.44-48. ISSN 0004-0614.

Objectives: To evaluate the toxicity and outcomes of the allogeneic transplantation of peripheral blood hematopoietic stem-cells with low intensityconditioning (mini-alo Bone Marrow transplantation-BMT) in metastatic renal cell carcinoma refractory to at least one line of systemic treatment. Methods: From 30 patients submitted to the Sant Pau`s Hospital for immunotherapy between 1/2001 and 1/2003, six patients finally underwent mini-alo BMT within a clinical trial. Conditioning: Fludarabine: 30 minute IV infusion of 13 mg/m2 on days - 9, - 8, - 7, - 6 and - 5. Busulfan: 1 mg/kg (real weight) q 6 hours, PO on days - 6, -5, and - 4 (4 doses per day on days - 6 and - 5, and 2 doses only on day - 4, total number of doses 10). Results: Two patients achieved partial response, one patient stabilized disease, and two patients hadprogression on days + 30 and + 60. Therefore, 2/3 patients surviving more than six months achieved partial response. One patient died on day + 30 after acute hepatic graft-versus-host disease. Complete chimerism was demonstrated in all patients. Conclusions: The mimni-alo BMT is feasible inpatients with metastatic renal cell carcinoma and provides objective responses, although its efficacy should beconfirmed by phase III clinical trials.

Palavras-chave : Kidney cancer; Peripheral; Allogeneic cell transplant.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons